Charles River, WuXi PharmaTech CEOs Issue Joint Appeal For Shareholder Support For Deal
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The heads of the Massachusetts-based Charles River Laboratories and the Shanghai-headquartered WuXi PharmaTech issued a joint appeal calling for shareholders to rally in support of the proposed union of the two contract research organizations during near-simultaneous votes four weeks from now
You may also be interested in...
As Charles River And WuXi PharmaTech Count Down To Shareholder Votes On Proposed Merger, Research Analysts Predict Defeat
BEIJING - As Charles River Laboratories and WuXi PharmaTech count down toward crucial shareholder votes on Aug. 5 - on whether their proposed union should go forward or be shot down - the American and Chinese drug research outfits have issued a new call for ratification of the plan
As Charles River And WuXi PharmaTech Count Down To Shareholder Votes On Proposed Merger, Research Analysts Predict Defeat
BEIJING - As Charles River Laboratories and WuXi PharmaTech count down toward crucial shareholder votes on Aug. 5 - on whether their proposed union should go forward or be shot down - the American and Chinese drug research outfits have issued a new call for ratification of the plan
As Charles River And WuXi PharmaTech Count Down To Shareholder Votes On Proposed Merger, Research Analysts Predict Defeat
Charles River says the CRO's major pharma clients support the deal.